[Human recombinant interferon-B constructed on the basis of affinity-binding domain technology]

Summary

A novel chimeric protein combining a dextran-binding domain and human interferon-beta was engineered in E. coli. This fusion protein allows for the purification of active interferon-beta, demonstrating its potential for antiviral therapies.